Investing.com - Financial Markets Worldwide
Open in App

Aurobindo Pharma Ltd. (ARBN)

NSE
Symbol
Exchange
Currency
ARBN·NSE·INR
ARBNc1:NS·NSE·INR
ARBNc2:NS·NSE·INR
ARBNc3:NS·NSE·INR
ARBN·BSE·INR
Currency in INR
1,621.30
+13.30(+0.83%)
Closed·

ARBN Financial Summary

Key Ratios

P/E Ratio25.16
Price/Book2.54
Debt / Equity21.31%
Return on Equity9.93%
Dividend Yield0.00%
EBITDA67.80B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
2026
31/03
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa234,554.9248,553.8290,018.7317,237.3336,530.8
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa130,056.1132,137.1160,161.8182,398.7196,655.7
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa33,064.325,118.943,915.150,413.751,513.6
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa26,481.519,27531,729.734,858.835,047.5
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa339,217.2398,899.9450,715.1497,849.7585,021.5
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa81,559.8114,937.8121,991.3146,823.4180,390.1
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa245,740.5268,518.5298,508326,469.3378,828.1
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa12,128.94-4,802.93-12,589.8311,574.5313,559.86
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa50,164.823,867.524,345.239,246.255,263.7
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-32,115.6-39,777.5-42,559.5-18,758-34,586.1
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-29,692.718,144.18,004.21,197.8-12,691.5
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-11,6742,297.6-10,068.421,783.616,276.1
* In Millions of INR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 63.99%
Dividend Yield
-
Industry Median 0.66%
Annualized payout
-
Paid unevenly
5-Years Growth
-
Growth Streak
Unlock

Analyst Ratings

18 Buy
5 Hold
4 Sell
Ratings:
27 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,678.32
(+3.52% Upside)

Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
17.86 / 17.33
Revenue / Forecast
91.5B / 90.3B
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Aurobindo Pharma's earnings for the latest quarter?

The Aurobindo Pharma EPS (TTM) is 63.99. Aurobindo Pharma reported sales of 91,503.50, net income of 10,325.60, and EPS of 17.86 for the latest quarter.

What was Aurobindo Pharma's net income for the latest quarter?

Aurobindo Pharma's net income for the latest quarter was 10,325.60.

How did Aurobindo Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 88,533.40 million INR in the previous quarter to 91,503.50 million INR in the latest quarter, and net income moved from 9,212.60 million INR to 10,325.60 million INR compared to the previous quarter.

What is Aurobindo Pharma's net profit margin on a TTM basis?

Aurobindo Pharma's trailing twelve months (TTM) net profit margin is 10.63%.

How does Aurobindo Pharma's debt to equity ratio compare to industry standards?

Aurobindo Pharma's total debt-to-equity ratio is 21.31%.

What is Aurobindo Pharma's return on investment on a TTM basis?

Aurobindo Pharma's trailing twelve months (TTM) return on investment (ROI) is 9.93%.

How has Aurobindo Pharma's total revenue grown this year?

Aurobindo Pharma's total revenue was 88,533.40 million INR in the previous quarter and 91,503.50 million INR in the latest quarter.

What is Aurobindo Pharma's gross margin on a TTM basis?

Aurobindo Pharma's trailing twelve months (TTM) gross margin is 58.85%%.

What was Aurobindo Pharma's revenue per share for the latest quarter?

Aurobindo Pharma's revenue per share for the latest quarter was 342.53.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.